News

Nutriband to Attend 2023 BIO International Convention

ORLANDO, FL / ACCESSWIRE / May 10, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it will be attending the Biotechnology Innovation Organization (BIO) International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA. The BIO Convention is the premier life …

Nutriband to Attend 2023 BIO International Convention Read More »

Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023

ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended January 31, 2023. Key Highlights: Generated record revenue of $2.1 million, up 46% over the prior fiscal year Successfully obtained court verdict for recovery of …

Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023 Read More »

Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023

Orlando, FL / ACCESSWIRE / April 19, 2023 / Nutriband Inc. (Nasdaq: NTRB) (Nasdaq: NTRBW), a pioneer in the development of innovative transdermal solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 08:30 AM (Local Time -PST). Company CEO, Gareth Sheridan will be …

Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 Read More »

Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development

ORLANDO, FL / ACCESSWIRE / April 4, 2023 / Nutriband Inc.(“Company”) (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery (“Kindeva”) have selected the target AVERSA™ formulation to take forward into commercial scale manufacturing process development for the Company’s patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband’s proprietary transdermal abuse deterrent technology which …

Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development Read More »

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. (“Company”) (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA approval process into commercial scale manufacturing for the Company’s patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband’s proprietary transdermal abuse deterrent …

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology Read More »

Nutriband Inc Joins Webull Corporate Communications Service Platform

ORLANDO, FL / ACCESSWIRE / March 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has joined Webull’s Corporate Communications Service Platform, which will provide Nutriband with a comprehensive suite of investor relations and corporate communications solutions. This will enable Nutriband to enhance its corporate communications efforts, expand its investor outreach, and increase its visibility …

Nutriband Inc Joins Webull Corporate Communications Service Platform Read More »

Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee

ORLANDO, FL / ACCESSWIRE / March 2, 2023 / Nutriband Inc. (the “Company”) (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that Alan Smith, Ph.D., Chief Operating Officer (COO), Nutriband, and President of its subsidiary, 4P Therapeutics LLC (“4P Therapeutics”), has been selected for the FDA’s Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for Transdermal/Topical Delivery …

Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee Read More »

Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador’s Health Register

ORLANDO, FL / ACCESSWIRE / February 15, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its has completed the requirements to file its application with Ecuador’s Health Register (Registro Sanitar Ecuador) to permit the distribution of certain medical devices and cosmetic products in South America. Ecuador is part of the Andean Community CAN. which provides access …

Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador’s Health Register Read More »

Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference

ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company’s participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom. Gareth Sheridan, Nutriband’s …

Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference Read More »

Nutriband Inc. Commences Trading on Upstream Under NTRB

Nutriband among the first issuers to dual list on Upstream ORLANDO, FL ACCESSWIRE / January 5, 2023 /  Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading …

Nutriband Inc. Commences Trading on Upstream Under NTRB Read More »